Gyre Therapeutics, Inc. (GYRE)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 30.6M | 37.2M | 22.5M | 29.1M |
| Gross Profit | 28.9M | 35.5M | 21.3M | 26.9M |
| Operating Income | 6.9M | 120K | (6.8M) | (13.9M) |
| Net Income | 3.6M | (1.7M) | (8.7M) | (10.6M) |
| Diluted EPS | $0.03 | $-0.02 | $-0.10 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 102.3M | 113.5M | 105.8M | 116.6M |
| Gross Profit | 97.5M | 108.8M | 101.9M | 111.2M |
| Operating Income | 9.2M | 19.2M | 16.2M | 11.5M |
| Net Income | 2.3M | (92.9M) | 12.1M | 5.0M |
| Diluted EPS | $0.03 | $-1.41 | $0.05 | $0.02 |